Adagene Announces Six-Month 2025 Financial Results and Clinical Progress for Muzastotug in MSS CRC

Adagene, a biotechnology company focused on developing innovative antibody-based therapies, has published its financial results for the first half of 2025, accompanied by significant corporate and clinical updates. The company provided detailed insights into the progress of its clinical programs, particularly regarding its drug candidate Muzastotug (ADG126), which is being evaluated for the treatment of microsatellite stable colorectal cancer (MSS CRC). In the Phase 1b/2 clinical trials for Muzastotug, Adagene reported a median overall survival (mOS) of 19.4 months in patients treated with the 10 mg/kg dose cohorts. For patients in the 20 mg/kg dose cohorts, the mOS has not yet been reached, indicating ongoing survival beyond the current data cutoff. These results highlight the potential efficacy of Muzastotug in addressing MSS CRC, a condition known for its challenging treatment landscape. Beyond the clinical data, Adagene has also achieved alignment with the U.S. Food and Drug Administration (FDA) on the design and execution of its upcoming Phase 2 and Phase 3 trials for Muzastotug. This regulatory milestone is a critical step in advancing the drug candidate toward potential approval and broader patient access. The company did not disclose specific details regarding the trial designs or timelines in the provided information. Adagene’s updates reflect its ongoing commitment to developing novel therapies for difficult-to-treat cancers. The financial results for the six-month period of 2025 were not detailed in the excerpt, but the focus on clinical progress underscores the company’s strategic priorities. Further information on financial performance and additional corporate developments may be available in the full report.